

CAS ONLINE PRINTOUT 09/816,317

=> d his

(FILE 'HOME' ENTERED AT 08:11:23 ON 09 OCT 2003)

FILE 'REGISTRY' ENTERED AT 08:11:27 ON 09 OCT 2003

L1 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L2 STRUCTURE UPLOADED
L3 QUE L2 NOT L1
L4 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L5 STRUCTURE UPLOADED
L6 QUE L5 NOT L4
L7 38 S L6 FUL CSS


FILE 'CAPLUS' ENTERED AT 08:13:19 ON 09 OCT 2003

L8 343 S L7
L9 169063 S INFLAMM?
L10 138050 S CYTOKINE?
L11 58619 S ARTHRITIS OR PNACREATITIS OR LUPUS OR ENCEPHALOMYELITIS OR GL
L12 6640 S PANCREATITIS
L13 318151 S L11 OR L12 OR L10 OR L9
L14 3 S L13 AND L8

=> d l5

L5 HAS NO ANSWERS

L5 STR



G1 OH, MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, t-BuO, X

G2 H, OH, MeO, X

Structure attributes must be viewed using STN Express query preparation.


=> d bib abs hitstr l14 1-3

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:977602 CAPLUS
DN 138:39143
TI Preparation of purines as inhibitors of phosphodiesterase VII (PDE7) for
therapeutic use in treating T-cell mediated diseases
IN Vaccaro, Wayne; Roberge, Jacques Y.; Leftheris, Katerina; Pitts, William
J.; Barbosa, Joseph
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent


LA English

FAN.CNT 6


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102314	A2	20021227	WO 2002-US19126	20020617
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003092721	A1	20030515	US 2002-173322	20020617
	US 2003100571	A1	20030529	US 2002-173530	20020617
PRAI	US 2001-299287P	P	20010619		
	US 2002-368752P	P	20020329		
OS	MARPAT 138:39143				
GI					



I



II



III


AB Purines, such as I and II [R1 = H, alkyl; R2 = heteroaryl, heterocyclyl, aryl; J = H, halogen, alkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, etc.; Y = alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl; Z = alkoxy, alkylthio, alkylamino, alkylsulfonylamino aryloxy, arylthio, arylamino, arylsulfonylamino, heteroaryloxy, heteroarylthio, heteroarylamino, heteroarylsulfonylamino, etc.], were prepd. for pharmaceutical use as PDE7 inhibitors for use in treating T-cell mediated diseases, such as transplant rejection, rheumatoid arthritis, and juvenile diabetes. Thus, purine II (Z = 3-pyridinylmethyl) was prepd. starting from 2,6-dichloro-7-ethylpurine, 2-amino-4-methyl-5-thiazolecarboxylic acid Et ester and 3-pyridinemethanamine. The prepd. purines were assayed for inhibition of PDE in Hut78 cell lysate using an SPA specific for cAMP and were assayed for inhibition of prodn. and secretion of TNF.alpha. for leukocytes. Pharmaceutical compns. were also discussed.

IT 119999-69-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of purines as inhibitors of phosphodiesterase VII (PDE7) for therapeutic use in treating T-cell mediated diseases)


RN 119999-69-8 CAPLUS
 CN 1-Naphthalenamine, 1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:543041 CAPLUS
 DN 129:161424
 TI Preparation of (S)-2-amino-6-fluoro-7-methoxytetraline for treatment of septic shock.
 IN Moretti, Gian Piero; Foresta, Piero
 PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9833762	A1	19980806	WO 1998-IT11	19980128
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 968174	A1	20000105	EP 1998-902173	19980128
	EP 968174	B1	20030122		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001509802	T2	20010724	JP 1998-532693	19980128
	AT 231486	E	20030215	AT 1998-902173	19980128
	ES 2190581	T3	20030801	ES 1998-902173	19980128
	US 6225501	B1	20010501	US 1999-341762	19990716
PRAI	IT 1997-RM50	A	19970203		
	WO 1998-IT11	W	19980128		

GI




AB S(-)-amino-6-fluoro-7-methoxytetraline (I) and salts thereof were prepd. Thus, L-aspartic acid was refluxed with (F3CCO)2O in CF3CO2H to give 95% N-trifluoroacetylaspargic anhydride. This was stirred with 2-fluoroanisole and AlCl3 to give 78.3% (S)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-(N-trifluoroacetyl)aminobutanoic acid. The latter was treated with Et3SiH in refluxing CF3CO2H to give 75% (S)-4-(3-fluoro-4-methoxyphenyl)-2-(N-trifluoroacetyl)aminobutanoic acid. The acid in CH2Cl2 was treated with PCl5 and then with AlCl3 at -20.degree.-reflux to give 60.4% (S)-(N-trifluoroacetyl)amino-6-fluoro-7-methoxy-1-tetralone. Treatment of the latter with Et3SiH in BF3.Et2O at 0.degree.-room temp. gave 78.63%

(S)-(N-trifluoroacetyl)amino-6-fluoro-7-methoxytetraline. This was refluxed with K₂CO₃ in MeOH/H₂O to give 52.8% I.HCl (ST 1214). ST 1214 at 6 mg/kg i.v. in mice reduced lethality induced by E. coli or S. typhosa LPS by 37% and 65%, resp.

IT 211173-67-0P, (S)-2-Amino-6-fluoro-7-methoxytetraline
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of (S)-2-amino-6-fluoro-7-methoxytetraline for treatment of **septic** shock)
 RN 211173-67-0 CAPLUS
 CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-7-methoxy-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:649632 CAPLUS
 DN 125:266047
 TI Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of **septic** shock, and antipyretic and anti-**inflammatory** pharmaceutical compositions
 IN Foresta, Piero; Ruggiero, Vito
 PA Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Italy
 SO Eur. Pat. Appl., 16 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 730861	A1	19960911	EP 1996-102860	19960226
	EP 730861	B1	20000802		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 195072	E	20000815	AT 1996-102860	19960226
	ES 2150034	T3	20001116	ES 1996-102860	19960226
	US 5591777	A	19970107	US 1996-607452	19960227
	TW 471967	B	20020111	TW 1996-85102443	19960229
	CA 2171081	AA	19960910	CA 1996-2171081	19960305
	ZA 9601897	A	19960912	ZA 1996-1897	19960308
	JP 08268884	A2	19961015	JP 1996-53075	19960311

PRAI IT 1995-RM143 A 19950309

OS MARPAT 125:266047

AB The use of 6,7-substituted-2-aminotetralines (e.g. 2-amino-6-fluoro-7-methoxytetraline) is disclosed for prepg. pharmaceutical compns. useful for the treatment of **septic** shock and having anti-**inflammatory** and antipyretic activities. Oral administration of 2-amino-6-fluoro-7-methoxytetraline (ST 626) at doses of 10, 20, and 50 mg/kg was able to decrease Brewer's yeast-induced pyrexia, as evaluated by rectal temp. measurements. Moreover, edema, developing as a consequence of the treatment with the phlogistic agent, was kept at lower values following treatment with ST 626.

CAS ONLINE PRINTOUT 09/816,317


IT 140914-59-6, ST 626

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aminotetralines for pharmaceutical compns. useful for treatment of **septic** shock and as antipyretics and **inflammation** inhibitors)

RN 140914-59-6 CAPLUS

CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-7-methoxy- (9CI) (CA INDEX NAME)



=>

CAS ONLINE PRINTOUT 09/816,317

=> d his

(FILE 'HOME' ENTERED AT 08:11:23 ON 09 OCT 2003)

FILE 'REGISTRY' ENTERED AT 08:11:27 ON 09 OCT 2003

L1 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L2 STRUCTURE UPLOADED
L3 QUE L2 NOT L1
L4 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L5 STRUCTURE UPLOADED
L6 QUE L5 NOT L4
L7 38 S L6 FUL CSS

FILE 'CAPLUS' ENTERED AT 08:13:19 ON 09 OCT 2003

L8 343 S L7
L9 169063 S INFLAMM?
L10 138050 S CYTOKINE?
L11 58619 S ARTHRITIS OR PNACREATITIS OR LUPUS OR ENCEPHALOMYELITIS OR GL
L12 6640 S PANCREATITIS
L13 318151 S L11 OR L12 OR L10 OR L9
L14 3 S L13 AND L8
SELECT PN L14 1-3

FILE 'USPATFULL' ENTERED AT 08:18:09 ON 09 OCT 2003

L15 4 S E1-E17

FILE 'REGISTRY' ENTERED AT 08:20:56 ON 09 OCT 2003

E ST1275/CN
E ST 1275/CN
E 2-AMINO-6-FLUORO-7-METHYLTETRALINE/CN

FILE 'REGISTRY' ENTERED AT 08:33:03 ON 09 OCT 2003

L16 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L17 STRUCTURE UPLOADED
L18 QUE L17 NOT L16
L19 0 S L17 CSS
L20 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L21 STRUCTURE UPLOADED
L22 QUE L21 NOT L20
L23 4 S L22 CSS
L24 23 S L22 CSS FUL

FILE 'CAPLUS' ENTERED AT 08:35:23 ON 09 OCT 2003

L25 325 S L24
L26 2 S L25 AND L13

FILE 'REGISTRY' ENTERED AT 08:43:49 ON 09 OCT 2003

L27 SCREEN 963
L28 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L29 STRUCTURE UPLOADED
L30 QUE L29 AND L27 NOT L28
L31 0 S L30 CSS
L32 0 S L30 CSS FUL

FILE 'BEILSTEIN' ENTERED AT 08:44:55 ON 09 OCT 2003

L33 0 S L29
L34 0 S L29 FUL


FILE 'REGISTRY' ENTERED AT 08:46:48 ON 09 OCT 2003

L35 0 S L29
L36 4 S L29 FUL

=> d 129

L29 HAS NO ANSWERS

L29 STR



G1 OH, MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, t-BuO, X, Ak

G2 H, OH, MeO, X

Structure attributes must be viewed using STN Express query preparation.

=> d ide bib abs 1-4

L36 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN


RN 221384-94-7 REGISTRY

CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-7-methyl-, hydrochloride
(9CI) (CA INDEX NAME)

MF C11 H14 F N . Cl H

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 130:237373 CA

TI Preparation of 2-aminotetralines for the prevention and treatment of
inflammatory and/or autoimmune pathologies.

IN Fanto, Nicola; Moretti, Gian Piero; Foresta, Piero

PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy

SO PCT Int. Appl., 69 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915494	A1	19990401	WO 1998-IT252	19980922
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2303943	AA	19990401	CA 1998-2303943	19980922
	AU 9893662	A1	19990412	AU 1998-93662	19980922
	AU 738565	B2	20010920		
	EP 1017667	A1	20000712	EP 1998-946706	19980922
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9812368	A	20000919	BR 1998-12368	19980922
	JP 2001517649	T2	20011009	JP 2000-512805	19980922
	NZ 503492	A	20020828	NZ 1998-503492	19980922
	US 2002123652	A1	20020905	US 2000-533381	20000322
	US 2003158266	A1	20030821	US 2001-816317	20010326
PRAI	IT 1997-RM568		19970922		
	WO 1998-IT252		19980922		
	US 2000-533381		20000322		
GI					



AB Title compds. [I; R, R1 = halo, OH, (substituted) alkoxy, alkanoyl, alkyl, carbamoyl, carbamoyloxy, amino, etc.; R2 = H, halo, OH, MeO; with provisos], and salts thereof, were prepd. Thus, (R)-(+)-2-amino-6-fluoro-7-hydroxytetralin hydrochloride (prepd. in several steps from D-aspartic acid and 2-fluoroanisole) at 18 mg/kg i.v. improved survival in E. coli LPS-treated mice by 44%.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L36 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN

RN 70153-83-2 REGISTRY

CN 1(2H)-Naphthalenone, 2-amino-6-chloro-3,4-dihydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)

MF C11 H12 Cl N O . Cl H

LC STN Files: CA, CAPLUS




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1

AN 91:20185 CA
TI Cyclic aminoalcohols
IN Hiraoka, Masayuki; Fukami, Hideo; Fukumori, Satoshi; Mizusawa, Hidetoshi;
Fujihara, Hiroshi; Yasui, Bompei
PA Funai Pharmaceutical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 54003047	A2	19790111	JP 1977-67585	19770608
	JP 60045179	B4	19851008		
PRAI	JP 1977-67585		19770608		
GI					




I



II



III



IV

AB Twenty-two title compds. I.HCl (R = aryloxy, aralkyl, aryl, cyclic alkyl, alkyl; R1 = H, alkyl, halo; or R R1 = alkylene) were prepd. by redn. of II or III or by hydrolysis of IV (R2 = alkyl, etc.). I had coronary vasodilating and heart muscle contraction inhibitory activities and are useful as remedies for angina pectoris (data given in the isolated guinea pig heart by Langendorff method). Thus, refluxing 3 g IV (R = PhO, R1 = H, R2 = Me) with 100 mL 0.1% HCl 12 h gave cis-I HCl (R = PhO, R1 = H).

L36 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN

RN 70153-48-9 REGISTRY

CN 1-Naphthalenol, 2-amino-6-chloro-1,2,3,4-tetrahydro-7-methyl-,


hydrochloride, trans- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C11 H14 Cl N O . Cl H

LC STN Files: CA, CAPLUS

Relative stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 91:20185 CA

TI Cyclic aminoalcohols

IN Hiraoka, Masayuki; Fukami, Hideo; Fukumori, Satoshi; Mizusawa, Hidetoshi; Fujihara, Hiroshi; Yasui, Bompei

PA Funai Pharmaceutical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 15 pp.


CODEN: JKXXAF

DT Patent


LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 54003047	A2	19790111	JP 1977-67585	19770608
	JP 60045179	B4	19851008		
PRAI	JP 1977-67585		19770608		
GI					




I



II



III




IV

AB Twenty-two title compds. I.HCl (R = aryloxy, aralkyl, aryl, cyclic alkyl,

alkyl; R1 = H, alkyl, halo; or R R1 = alkylene) were prepd. by redn. of II or III or by hydrolysis of IV (R2 = alkyl, etc.). I had coronary vasodilating and heart muscle contraction inhibitory activities and are useful as remedies for angina pectoris (data given in the isolated guinea pig heart by Langendorff method). Thus, refluxing 3 g IV (R = PhO, R1 = H, R2 = Me) with 100 mL 0.1% HCl 12 h gave cis-I HCl (R = PhO, R1 = H).

L36 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 70153-39-8 REGISTRY
 CN 1-Naphthalenol, 2-amino-6-chloro-1,2,3,4-tetrahydro-7-methyl-,
 hydrochloride, cis- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C11 H14 Cl N O . Cl H
 LC STN Files: CA, CAPLUS

Relative stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1

AN 91:20185 CA
 TI Cyclic aminoalcohols
 IN Hiraoka, Masayuki; Fukami, Hideo; Fukumori, Satoshi; Mizusawa, Hidetoshi;
 Fujihara, Hiroshi; Yasui, Bompei
 PA Funai Pharmaceutical Industries, Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 54003047	A2	19790111	JP 1977-67585	19770608
	JP 60045179	B4	19851008		
PRAI	JP 1977-67585		19770608		
GI					




I



II



III



IV

AB Twenty-two title compds. I.HCl (R = aryloxy, aralkyl, aryl, cyclic alkyl, alkyl; R¹ = H, alkyl, halo; or R R¹ = alkylene) were prepd. by redn. of II or III or by hydrolysis of IV (R² = alkyl, etc.). I had coronary vasodilating and heart muscle contraction inhibitory activities and are useful as remedies for angina pectoris (data given in the isolated guinea pig heart by Langendorff method). Thus, refluxing 3 g IV (R = PhO, R¹ = H, R² = Me) with 100 mL 0.1% HCl 12 h gave cis-I HCl (R = PhO, R¹ = H).

=>